Skinvisible, Inc. (SKVI) stock
SKVIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 0/30
$0.16+0.00 (+0.06%)
Close on Oct 19, 2026Market cap $843.54KP/E –Yield –
Skinvisible ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Skinvisible's ebitda for the twelve months ending Jun 30, 2026 was -$438.74K. For fiscal 2025 it was -$476.08K. The highest annual figure on record is $206.02K in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$476.08K | – |
| FY2024 | Dec 31, 2024 | -$569.15K | – |
| FY2023 | Dec 31, 2023 | -$471.60K | – |
| FY2022 | Dec 31, 2022 | -$219.69K | -206.6% |
| FY2021 | Dec 31, 2021 | $206.02K | – |
| FY2020 | Dec 31, 2020 | -$221.64K | – |
| FY2019 | Dec 31, 2019 | -$500.16K | – |
| FY2018 | Dec 31, 2018 | -$558.96K | – |
| FY2017 | Dec 31, 2017 | -$309.74K | – |
| FY2016 | Dec 31, 2016 | -$784.06K | – |
| FY2015 | Dec 31, 2015 | -$1.02M | – |
| FY2014 | Dec 31, 2014 | -$1.13M | – |
| FY2013 | Dec 31, 2013 | -$722.33K | – |
| FY2012 | Dec 31, 2012 | -$1.27M | – |
| FY2011 | Dec 31, 2011 | -$1.17M | – |
| FY2010 | Dec 31, 2010 | -$758.31K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$107.82K | – |
| Q1 FY2026 | Mar 31, 2026 | -$120.93K | – |
| Q4 FY2025 | Dec 31, 2025 | -$109.05K | – |
| Q3 FY2025 | Sep 30, 2025 | -$100.94K | – |
| Q2 FY2025 | Jun 30, 2025 | -$131.17K | – |
| Q1 FY2025 | Mar 31, 2025 | -$134.91K | – |
| Q4 FY2024 | Dec 31, 2024 | -$193.69K | – |
| Q3 FY2024 | Sep 30, 2024 | -$119.03K | – |
| Q2 FY2024 | Jun 30, 2024 | -$137.94K | – |
| Q1 FY2024 | Mar 31, 2024 | -$118.49K | – |
| Q4 FY2023 | Dec 31, 2023 | -$131.79K | – |
| Q3 FY2023 | Sep 30, 2023 | -$108.57K | – |
| Q2 FY2023 | Jun 30, 2023 | -$107.98K | -170.9% |
| Q1 FY2023 | Mar 31, 2023 | -$123.26K | – |
| Q4 FY2022 | Dec 31, 2022 | -$112.98K | -169.0% |
| Q3 FY2022 | Sep 30, 2022 | -$122.44K | – |
| Q4 FY2021 | Dec 31, 2021 | $152.24K | +866.0% |
| Q3 FY2021 | Sep 30, 2021 | -$3.16K | – |
| Q2 FY2021 | Jun 30, 2021 | $163.82K | – |
| Q1 FY2021 | Mar 31, 2021 | -$106.88K | – |
| Q4 FY2020 | Dec 31, 2020 | $15.76K | – |
| Q3 FY2020 | Sep 30, 2020 | -$114.33K | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.80K | – |
| Q1 FY2020 | Mar 31, 2020 | -$120.27K | – |
| Q4 FY2019 | Dec 31, 2019 | -$107.66K | – |
| Q3 FY2019 | Sep 30, 2019 | -$126.74K | – |
| Q2 FY2019 | Jun 30, 2019 | -$129.32K | – |
| Q1 FY2019 | Mar 31, 2019 | -$136.44K | – |
| Q4 FY2018 | Dec 31, 2018 | -$143.60K | -155.9% |
| Q3 FY2018 | Sep 30, 2018 | -$128.65K | – |
| Q2 FY2018 | Jun 30, 2018 | -$121.78K | – |
| Q1 FY2018 | Mar 31, 2018 | -$164.94K | – |
| Q4 FY2017 | Dec 31, 2017 | $257.01K | – |
| Q3 FY2017 | Sep 30, 2017 | -$127.10K | – |
| Q2 FY2017 | Jun 30, 2017 | -$299.44K | – |
| Q1 FY2017 | Mar 31, 2017 | -$140.22K | – |
| Q4 FY2016 | Dec 31, 2016 | -$138.80K | – |
| Q3 FY2016 | Sep 30, 2016 | -$187.35K | – |
| Q2 FY2016 | Jun 30, 2016 | -$158.30K | – |
See a number that looks wrong?